Contemporary patterns of local ablative therapies for prostate cancer at United States cancer centers: results from a national registry.
Contemporary patterns of local ablative therapies for prostate cancer at United States cancer centers: results from a national registry.
复制标题
DOI：
10.1007/s00345-023-04354-7
复制
发表时间：
2023-05
影响因子：
3.4
通讯作者：
Cole, Alexander P.
中科院分区：
文献类型：
--
作者：
Koelker, Mara;Labban, Muhieddine;Frego, Nicola;Meyer, Christian P.;Salomon, Georg;Lipsitz, Stuart R.;Withington, John;Moore, Caroline M.;Tempany, Clare M.;Tuncali, Kemal;George, Arvin;Kibel, Adam S.;Trinh, Quoc-Dien;Cole, Alexander P.
描述前列腺癌男性局部消融治疗的国家级护理模式，并确定与接受这些技术相关的患者和医院层面的因素。我们回顾性地查询了2010年至2017年间美国国家癌症数据库（NCDB）中临床上局限性前列腺癌的男性患者。主要结果是接受局部肿瘤消融，无论是低温消融还是激光消融，以及“其他局部肿瘤破坏方法，包括高强度聚焦超声（HIFU）”。收集了患者水平、医院水平和人口统计变量。采用混合效应logistic回归模型分别确定患者和医院层面接受局部消融治疗的预测因素。总体而言，11,278例患者接受了消融治疗，其中78.8%接受了冷冻治疗，15.6%接受了激光治疗，5.7%接受了包括HIFU在内的其他方法。在病人层面,中度风险PCa的男性更有可能与当地的烧蚀疗法治疗(或1.05;95%可信区间1.00 - -1.11;p = 0.05),与Charlson发病率是男性指数> 1(或1.36;95%可信区间1.29 - -1.43;p < 0.01),男性在71年和80年(或3.70;95%可信区间3.43 - -3.99;p < 0.01),男性医疗保险(1.31 - -1.46或1.38;95%;p < 0.01),和一个收入< 47999美元(或1.16;95%可信区间1.06 - -1.21;p < 0.01)。在医院层面，在学术/研究机构进行局部消融治疗的可能性较小（OR 0.45; 95% CI 0.32-0.64; p < 0.01）。局部消融治疗更常用于老年和合并症患者。未来的研究应调查这些技术在非医院环境中的采用情况，并考虑到最近保险范围的变化。
To describe the national-level patterns of care for local ablative therapy among men with PCa and identify patient- and hospital-level factors associated with the receipt of these techniques. We retrospectively interrogated the National Cancer Database (NCDB) for men with clinically localized PCa between 2010 and 2017. The main outcome was receipt of local tumor ablation with either cryo- or laser-ablation, and “other method of local tumor destruction including high-intensity focused ultrasound (HIFU)”. Patient level, hospital level, and demographic variables were collected. Mixed effect logistic regression models were fitted to identify separately patient- and hospital-level predictors of receipt of local ablative therapy. Overall, 11,278 patients received ablative therapy, of whom 78.8% had cryotherapy, 15.6% had laser, and 5.7% had another method including HIFU. At the patient level, men with intermediate-risk PCa were more likely to be treated with local ablative therapy (OR 1.05; 95% CI 1.00–1.11; p = 0.05), as were men with Charlson Comorbidity Index > 1 (OR 1.36; 95% CI 1.29–1.43; p < 0.01), men between 71 and 80 years (OR 3.70; 95% CI 3.43–3.99; p < 0.01), men with Medicare insurance (OR 1.38; 95% 1.31–1.46; p < 0.01), and an income < $47,999 (OR 1.16; 95% CI 1.06–1.21; p < 0.01). At the hospital-level, local ablative therapy was less likely to be performed in academic/research facilities (OR 0.45; 95% CI 0.32–0.64; p < 0.01). Local ablative therapy for PCa treatment is more commonly offered among older and comorbid patients. Future studies should investigate the uptake of these technologies in non-hospital-based settings and in light of recent changes in insurance coverage.
登录
查看更多内容
影响因子：
3.7
作者：
Bilimoria KY;Stewart AK;Winchester DP;Ko CY
通讯作者：
Ko CY
DOI：
10.1016/j.urolonc.2017.08.008
发表时间：
2018-04-01
影响因子：
2.7
作者：
Cole, Alexander P.;Friedlander, David F.;Quoc-Dien Trinh
通讯作者：
Quoc-Dien Trinh
DOI：
10.1016/j.urolonc.2019.10.015
发表时间：
2020-03-01
影响因子：
2.7
作者：
Quoc-Dien Trinh;Hong, Fangxin;Berry, Donna L.
通讯作者：
Berry, Donna L.
DOI：
10.1056/nejmoa1801993
发表时间：
2018-05-10
期刊：
The New England journal of medicine
影响因子：
--
作者：
通讯作者：
--
影响因子：
3.4
作者：
Westhoff N;Ernst R;Kowalewski KF;Schmidt L;Worst TS;Michel MS;von Hardenberg J
通讯作者：
von Hardenberg J